Skip to content

Study · Not a test of the peptide alone · 1996

3 results

GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans.

Bowers CY, Granda-Ayala R

Journal of pediatric endocrinology & metabolism : JPEM1 Jun 1996Cited by 9 (Europe PMC)

PMID8887169 (opens in a new tab)PepBankPUB-08887169
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 01HumanNot a test of GHRP-2 aloneNon-randomized trialActivity measurement

    In normal men and women, chronic GHRP‑2 or GHRH converted an additive GH response to GHRP‑2 plus GHRH into a synergistic one.

    In plain wordsIn healthy men and women, taking GHRP‑2 or GHRH for days turned an additive growth hormone response to both together into a synergistic one.

    Peptide
    GHRP-2
    Outcome
    IncreaseGH response to GHRP-2 plus GHRH after chronic GHRP-2 or GHRH
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    It was demonstrated that chronic administration of either GHRP-2 or GHRH could convert an additive GHRP-2 + GHRH GH response to a synergistic one.
    1 context sentence
    Summary · context
    Normal younger and older men and women received chronic GHRP-2, GHRH or GHRP-2 + GHRH for 7-30 days.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  2. 02HumanNot a test of GHRP-2 aloneNon-randomized trialActivity measurement

    In normal men and women, the type of synergistic GH response differed between chronic GHRP‑2 and chronic GHRH.

    In plain wordsIn healthy men and women, the kind of synergistic growth hormone response differed between chronic GHRP‑2 and chronic GHRH.

    Peptide
    GHRP-2
    Outcome
    MixedType of synergistic GH response, chronic GHRP-2 versus chronic GHRH
    Study

    n: not reported in source

    Comparator
    Chronic GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    In addition, the type of synergistic response induced by chronic GHRP-2 versus GHRH was different.
    1 context sentence
    Summary · context
    Normal younger and older men and women received chronic GHRP-2, GHRH or GHRP-2 + GHRH for 7-30 days.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  3. 03HumanNot a test of GHRP-2 aloneNon-randomized trialActivity measurement

    In normal men and women, whether the GH response became desensitized during chronic administration depended in part on dosage and frequency.

    In plain wordsIn healthy men and women, whether the growth hormone response weakened during repeated dosing depended partly on dose and how often it was given.

    Peptide
    GHRP-2
    Outcome
    MixedDesensitization of GH response during chronic administration
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Whether the GH response becomes desensitized during chronic administration depends in part on the dosage and frequency of administration.
    1 context sentence
    Summary · context
    Normal younger and older men and women received chronic GHRP-2, GHRH or GHRP-2 + GHRH for 7-30 days.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.